COVID-19 nucleic acid detection reagent obtains medical device registration certificate

Column:Company news Time:2020-06-10

After nearly three months of hard work, Anbio R & D and product registration team successfully developed COVID-19 nucleic acid detection reagent of hybrid capture immunofluorescence method,  passed the registration verification and clinical evaluation, and finally obtained medical device registration certificate.
The product has more efficient and convenient operation advantages, and is expected to contribute to the prevention and control of new coronavirus.